Adlai Nortye Biopharma Co., Ltd.

This early-phase study tests a new drug called AN4005 in about 31 adults with advanced solid tumors or lymphoma that has not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. Participants will r…

This early-phase study tests a new oral drug, AN9025, in people with advanced solid tumors that have specific RAS gene mutations. The main goal is to check the drug's safety and find the right dose. About 91 participants will take the drug daily and be monitored closely for side …